AR120120A1 - Composiciones de polímero líquido y sistemas para la administración prolongada de péptidos como ingredientes farmacéuticos activos - Google Patents
Composiciones de polímero líquido y sistemas para la administración prolongada de péptidos como ingredientes farmacéuticos activosInfo
- Publication number
- AR120120A1 AR120120A1 ARP200102708A ARP200102708A AR120120A1 AR 120120 A1 AR120120 A1 AR 120120A1 AR P200102708 A ARP200102708 A AR P200102708A AR P200102708 A ARP200102708 A AR P200102708A AR 120120 A1 AR120120 A1 AR 120120A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecular weight
- lactide
- active pharmaceutical
- block copolymer
- peptides
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 229920001400 block copolymer Polymers 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 abstract 1
- -1 D-lactide Chemical compound 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical group O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 abstract 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical group O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un producto, que comprende una composición de liberación prolongada caracterizado porque comprende: a) un ingrediente farmacéutico activo que comprende un péptido o un éster o sal aceptable desde el punto de vista farmacéutico de este, en donde el péptido comprende al menos un grupo amina accesible; b) un solvente biocompatible o una combinación o mezcla de solventes y/o cosolventes; y c) un copolímero en bloque líquido biodegradable que comprende: i) un bloque de copolímero que comprende: (1) residuos de monómeros seleccionados del grupo que consiste en D,L-lactida, D-lactida, L-lactida y glicólido, y combinaciones de estos y (2) residuos de monómeros seleccionados del grupo que consiste en e-caprolactona, carbonato de trimetileno y combinaciones de estos y tiene un peso molecular promedio en peso de entre 1 kDa y 35 kDa; y ii) un bloque de polímero que comprende un polietilenglicol (PEG) de bajo peso molecular que tiene un peso molecular promedio en número de 200 a 2000 daltones, en donde el copolímero en bloque líquido biodegradable se sintetiza mediante iniciación con el PEG de bajo peso molecular, y en donde la viscosidad del copolímero en bloque líquido biodegradable no aumenta de forma espontánea con un aumento de temperatura.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908340P | 2019-09-30 | 2019-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120120A1 true AR120120A1 (es) | 2022-02-02 |
Family
ID=72811904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102708A AR120120A1 (es) | 2019-09-30 | 2020-09-29 | Composiciones de polímero líquido y sistemas para la administración prolongada de péptidos como ingredientes farmacéuticos activos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220362383A1 (es) |
| EP (2) | EP4302773A1 (es) |
| JP (1) | JP2022551818A (es) |
| KR (1) | KR20220075338A (es) |
| CN (1) | CN114746080A (es) |
| AR (1) | AR120120A1 (es) |
| AU (1) | AU2020358364A1 (es) |
| BR (1) | BR112022004856A2 (es) |
| CA (1) | CA3154134A1 (es) |
| DK (1) | DK4037660T3 (es) |
| ES (1) | ES2966371T3 (es) |
| FI (1) | FI4037660T3 (es) |
| MX (1) | MX2022003246A (es) |
| TW (1) | TW202126321A (es) |
| UY (1) | UY38900A (es) |
| WO (1) | WO2021064550A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| AU2006278328A1 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| US7740877B2 (en) | 2006-04-07 | 2010-06-22 | University Of Utah Research Foundation | Aliphatically modified biodegradable block copolymers as thermogelling polymers |
| US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| ES2527193T3 (es) * | 2010-07-09 | 2015-01-21 | Innocore Technologies B.V. | Copolímeros multibloque segmentados de fases separadas biodegradables y liberación de polipéptidos biológicamente activos |
| ES2820369T3 (es) | 2011-03-31 | 2021-04-20 | Ingell Tech Holding B V | Composiciones biodegradables adecuadas para liberación controlada |
| US10239991B2 (en) * | 2014-05-01 | 2019-03-26 | Ingell Technologies Holding B.V. | Liquid triblock copolymer |
| WO2017024027A1 (en) | 2015-08-03 | 2017-02-09 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| US11752099B2 (en) * | 2017-03-27 | 2023-09-12 | W. L. Gore & Associates, Inc. | Injectable and biodegradable polymer formulations for controlled release of bioactive agents |
-
2020
- 2020-09-28 CN CN202080082220.7A patent/CN114746080A/zh active Pending
- 2020-09-28 MX MX2022003246A patent/MX2022003246A/es unknown
- 2020-09-28 DK DK20789268.8T patent/DK4037660T3/da active
- 2020-09-28 EP EP23209824.4A patent/EP4302773A1/en active Pending
- 2020-09-28 BR BR112022004856A patent/BR112022004856A2/pt unknown
- 2020-09-28 US US17/765,072 patent/US20220362383A1/en active Pending
- 2020-09-28 FI FIEP20789268.8T patent/FI4037660T3/fi active
- 2020-09-28 ES ES20789268T patent/ES2966371T3/es active Active
- 2020-09-28 KR KR1020227010674A patent/KR20220075338A/ko unknown
- 2020-09-28 EP EP20789268.8A patent/EP4037660B1/en active Active
- 2020-09-28 CA CA3154134A patent/CA3154134A1/en active Pending
- 2020-09-28 JP JP2022519471A patent/JP2022551818A/ja active Pending
- 2020-09-28 WO PCT/IB2020/059058 patent/WO2021064550A1/en unknown
- 2020-09-28 AU AU2020358364A patent/AU2020358364A1/en active Pending
- 2020-09-29 AR ARP200102708A patent/AR120120A1/es unknown
- 2020-09-30 TW TW109134017A patent/TW202126321A/zh unknown
- 2020-09-30 UY UY0001038900A patent/UY38900A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022551818A (ja) | 2022-12-14 |
| ES2966371T3 (es) | 2024-04-22 |
| BR112022004856A2 (pt) | 2022-06-07 |
| MX2022003246A (es) | 2022-04-26 |
| AU2020358364A1 (en) | 2022-03-31 |
| EP4037660A1 (en) | 2022-08-10 |
| KR20220075338A (ko) | 2022-06-08 |
| CA3154134A1 (en) | 2021-04-08 |
| DK4037660T3 (da) | 2024-01-02 |
| EP4302773A1 (en) | 2024-01-10 |
| TW202126321A (zh) | 2021-07-16 |
| WO2021064550A1 (en) | 2021-04-08 |
| EP4037660B1 (en) | 2023-11-22 |
| CN114746080A (zh) | 2022-07-12 |
| UY38900A (es) | 2021-04-30 |
| US20220362383A1 (en) | 2022-11-17 |
| FI4037660T3 (fi) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | Thermosensitive PEG–PCL–PEG hydrogel controlled drug delivery system: sol–gel–sol transition and in vitro drug release study | |
| RU2010130427A (ru) | Мицеллярная композиция амфифильного блоксополимера, содержащая таксан, и способ ее получения | |
| Gong et al. | Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel | |
| EP1716847B1 (en) | Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer | |
| US9364442B2 (en) | Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides | |
| JP2011503183A5 (es) | ||
| US9155722B2 (en) | Reconstitutable reverse thermal gelling polymers | |
| WO2012131104A3 (en) | Biodegradable compositions suitable for controlled release | |
| JP2015522001A5 (es) | ||
| RU2017111079A (ru) | Фармацевтическая композиция с улучшенной стабильностью | |
| BR9914258B1 (pt) | Polímero triboloco biodegradável e composição polimérica aquosa biodegradável | |
| AR113097A1 (es) | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos | |
| EA033537B1 (ru) | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью | |
| WO2002085337B1 (en) | Micellar drug delivery systems for hydrophobic drugs | |
| RU2320321C2 (ru) | Композиции депо кратковременного действия | |
| RU2018105494A (ru) | Улучшенные системы доставки наночастиц | |
| AR120120A1 (es) | Composiciones de polímero líquido y sistemas para la administración prolongada de péptidos como ingredientes farmacéuticos activos | |
| DE69923795T2 (de) | Verfahren zur Herstellung biologisch-abbaubarer Polyester | |
| JP7225486B2 (ja) | 癒着防止用アミノ酸修飾ポリマーおよびその用途 | |
| Yang et al. | Highly efficient cross-linking of poly (trimethylene carbonate) via bis (trimethylene carbonate) or bis (ε-caprolactone) | |
| AR123662A1 (es) | Composiciones y sistemas de polímeros y solventes biodegradables para un almacenamiento extendido y suministro de ingredientes farmacéuticos activos | |
| RU2012145462A (ru) | Эмульсии для микрокапсулирования, содержащие биоразлагаемые поверхностно-активные блок-сополимеры в качестве стабилизаторов | |
| NZ730538B2 (en) | Pharmaceutical composition with improved stability | |
| Arimura et al. | Preparation of polylactide microspheres having positively or negatively charged surfaces | |
| FI3908321T3 (fi) | Farmaseuttinen koostumus |